GlassScriptPhysician profile
Prudhvi Regula
NPI 1386139244
$1,392.33
in general payments reported to CMS, 2019-2025
13 companies · $599 in 2025
The $599 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $339 · 2024: $454 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,384 · Education: $8.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,384.08 |
| Education | $8.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $454.72 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $260.62 | 2023-2025 | Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $204.86 | 2023-2025 | Dupixent |
| Glaxosmithkline, LLC. | $134.40 | 2023-2025 | Nucala, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $60.09 | 2023-2025 | |
| Csl Behring | $57.04 | 2023-2025 | Haegarda, Hizentra |
| Amgen INC. | $53.00 | 2023-2025 | Tezspire |
| Genentech USA, INC. | $37.27 | 2025 | Xolair |
| Galderma Laboratories, L.P. | $36.61 | 2025 | Nemluvio |
| Aurinia Pharma U.S., INC. | $29.21 | 2023 | Lupkynis |
| Biocryst US Sales Co., LLC | $28.65 | 2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $19.22 | 2025 | Cuvitru |
| Ars Pharmaceuticals Operations, INC. | $16.64 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prudhvi Regula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.